Davion Healthcare Plc, a leading medical device manufacturer, has entered into an agreement with The Bank of New York Mellon to launch an American depositary receipts programme (ADR) and conduct an IPO fundraising round of $30 million U.S. dollars in preparation for the listing of its depositary receipts on the NASDAQ Stock Exchange.
Jack Kaye, CEO of Davion, commented: “We are thrilled to be working with The Bank of New York Mellon on this exciting endeavour. Their extensive experience and unrivalled expertise in managing ADR programmes makes them an ideal partner for us. We greatly value their contribution to our fundraising efforts and their commitment to our future success.”
The $30 million IPO fundraising round will be allocated towards expanding operations, investing in product research and development, and also strengthening sales and marketing efforts internationally.
Munro Forbes, Media Relations Manager at Davion, added: “We are enthusiastic about the prospects of this fundraising round and subsequent listing. This will not only fuel our growth but also provide an attractive investment opportunity for potential investors. We are confident that with the support of The Bank of New York Mellon and the robust ecosystem of the NASDAQ stock exchange, we will achieve meaningful milestones in the upcoming months.”
Davion anticipates that the IPO fundraising round and subsequent listing on the NASDAQ stock exchange will take place in the first quarter of 2024, subject to market forces. The company remains committed to delivering exceptional value to its shareholders whilst driving innovation within the medical sector.
Davion Healthcare Plc has entered into an agreement with The Bank of New York Mellon for an American Depositary Receipts (ADR) programme and $30 million Initial Public Offering (IPO) fundraising round.
The strategic relationship will enable the company to broaden its investor base, enhance global visibility and pave the way for future opportunities. The ADR issuance will enable investors to easily invest in Davion through the U.S. securities market, providing them with increased accessibility and liquidity.
Jack Kaye, CEO of Davion, said: “We are thrilled to be working with The Bank of New York Mellon on this exciting endeavour. Their extensive experience and unrivalled expertise in managing ADR programmes makes them an ideal partner for us. We greatly value their contribution to our fundraising efforts and their commitment to our future success.”
The $30 million IPO fundraising round will be allocated towards expanding operations, investing in product research and development, and also strengthening sales and marketing efforts internationally. The successful completion of this fundraising round will position Davion one step closer to its anticipated listing on the prestigious NASDAQ Stock Exchange.
Munro Forbes, Media Relations Manager at Davion, commented: “We are enthusiastic about the prospects of this fundraising round and subsequent listing. This will not only fuel our growth but also provide an attractive investment opportunity for potential investors. We are confident that with the support of The Bank of New York Mellon and the robust ecosystem of the NASDAQ stock exchange, we will achieve meaningful milestones in the upcoming months.”
Davion Healthcare Plc has entered into an agreement with The Bank of New York Mellon to launch an American depositary receipts programme (ADR) and conduct an IPO fundraising round of $30 million U.S. dollars in preparation for listing its depositary receipts on the NASDAQ Stock Exchange.
Jack Kaye, CEO of Davion, stated: “We are thrilled to be working with The Bank of New York Mellon on this exciting endeavour. Their extensive experience and unrivalled expertise in managing ADR programmes makes them an ideal partner for us. We greatly value their contribution to our fundraising efforts and their commitment to our future success.”
The $30 million IPO fundraising round will be used to expand operations, invest in product research and development, and strengthen sales and marketing efforts internationally.
Munro Forbes, Media Relations Manager at Davion, added: “We are enthusiastic about the prospects of this fundraising round and subsequent listing. This will not only fuel our growth but also provide an attractive investment opportunity for potential investors. We are confident that with the support of The Bank of New York Mellon and the robust ecosystem of the NASDAQ stock exchange, we will achieve meaningful milestones in the upcoming months.”
Davion Healthcare Plc has entered into an agreement with The Bank of New York Mellon, a renowned financial institution, to launch an American depositary receipts programme (ADR) and conduct an IPO fundraising round of $30 million U.S. dollars. The funds raised will be used to expand operations, invest in product research and development and strengthen sales and marketing efforts internationally.
Jack Kaye, CEO of Davion, commented: “We are thrilled to be working with The Bank of New York Mellon
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.